PhaseBio Pharmaceuticals Inc. (PHAS) Prices 16M Share Common Offering at $3.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock
March 17, 2021 5:02 PM EDTPhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of... More
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to 'Street High' $19 at Needham & Company
March 16, 2021 10:44 AM EDTNeedham & Company analyst Chad Messer raised the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) a 'Street High' to $19.00 (from $18.00) while maintaining a Buy rating.
... MorePhaseBio Pharmaceuticals Inc. (PHAS) Halted on LUDP, Up 12%
March 16, 2021 10:42 AM EDTPhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) Halted on LUDP, Up 12%
